

Krakow, 29<sup>th</sup> March 2024

## REQUEST FOR QUOTATION No. ABM- 29 03 2024 B

In connection with the implementation by Ryvu Therapeutics S.A. of the project ‘The conduct of a phase II, multicentre, open-label clinical trial (RIVER-81) evaluating the safety and efficacy of RVU120 in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia who have failed prior therapy with venetoclax and a hypomethylating agent’ (the ‘Project’) under the Competition: Development of targeted or personalized medicine based on therapeutic products based on nucleic acids and small-molecule compounds ABM/2022/6 organized by the Medical Research Agency, Ryvu Therapeutics S.A. invites quotes for the execution of the following defined order description.

### I. ORDERING PARTY

Ryvu Therapeutics S.A.  
 Sternbacha 2, 30-394 Krakow, Poland  
 EU VAT PL6792942955

### II. ORDER DESCRIPTION

In the scope of the order description is the sale and delivery of the following products:

#### Part 1

| No. | Name and Description   | Package size | Quantity |
|-----|--|--------------|----------|
| 1.  | <b>Human Genome 80K Knockout Libraries</b> <ul style="list-style-type: none"> <li>• Single library with ~80,000 constructs</li> <li>• Each gene is targeted by 4 sgRNAs</li> <li>• Vector: RFP and Puro Plasmid (pRSG16-U6-sg-UbiC-TagRFP-2A-Puro vector)</li> </ul> | 200ug        | 1        |

#### Part 2

| No. | Name and Description  | Package size | Quantity |
|-----|---|--------------|----------|
| 1.  | <b>Monoclonal antibody CD235a / Glycophorin A (extracellular domain)</b> <ul style="list-style-type: none"> <li>• Clone: 256</li> <li>• Conjugated with: Allophycocyanin (APC)</li> <li>• Isotype: Mouse IgG1, κ</li> </ul> | 100 tests    | 10       |

### Part 3

| No. | Name and Description   | Package size | Quantity |
|-----|--|--------------|----------|
| 1.  | <b>Mouse Anti-Human CD105 antibody</b> <ul style="list-style-type: none"> <li>• Isotype: IgG1, <math>\kappa</math></li> <li>• Immunogen: Human Umbilical Vein Endothelial Cells</li> <li>• Application: Flow cytometry</li> <li>• Vol per test: 5uL</li> <li>• Storage Buffer: Aqueous buffered solution containing BSA and <math>\leq 0.09\%</math> sodium azida</li> <li>• Conjugated with dye that has an excitation max at 348 nm and an emission max at 395 nm, for use with a 355nm laser equipped instrument</li> </ul> | 50 tests     | 8        |
| 2.  | <b>Sheath Fluid</b> <ul style="list-style-type: none"> <li>• Sodium azide-free</li> <li>• For use with flow cytometers</li> </ul>  | 20L          | 10       |

### Part 4

| No. | Name and Description   | Package size | Quantity |
|-----|--|--------------|----------|
| 1.  | <b>Recovery medium</b> <ul style="list-style-type: none"> <li>• For all competent cell transformations</li> <li>• Use in the outgrowth stage of competent cell transformation to attain up to 10-fold higher transformation efficiency</li> </ul>  | 8x12mL       | 1        |
| 2.  | <b>Elektrocompetent cells</b> <ul style="list-style-type: none"> <li>• For use in CRISPR library protocols and lentiviral guide RNA library generation</li> <li>• High efficiency cells for lentiviral cloning: over <math>1 \times 10^{10}</math> cfu/ug</li> <li>• 2 transformations per tube</li> <li>• Set containing Control DNA and Recovery Medium</li> </ul> | 10 tests     | 1        |

### Part 5

| No. | Name and Description  | Package size | Quantity |
|-----|---|--------------|----------|
| 1.  | <b>Phospho-S6 Ribosomal Protein Rabbit monoclonal antibody</b> <ul style="list-style-type: none"> <li>• Isotype: IgG</li> <li>• Reactivity: Human, Mouse, Rat, Monkey, Mink and <i>S. cerevisiae</i></li> <li>• Storage buffer: PBS (pH 7.2), less than 0.1% sodium azide and 2 mg/ml BSA</li> <li>• Detects endogenous levels of ribosomal protein S6 only when phosphorylated at Ser235 and 236</li> <li>• Application: Immunofluorescence, Flow cytometry</li> <li>• Conjugated with dye that has excitation max at <math>\sim 650</math>nm and emission max at <math>\sim 671</math>nm</li> </ul> | 100uL        | 2        |
| 2.  | <b>S6 Ribosomal Protein (54D2) Mouse monoclonal antibody</b> <ul style="list-style-type: none"> <li>• Isotype: IgG1</li> <li>• Reactivity: Human, Mouse, Rat, Monkey, <i>D. melanogaster</i></li> <li>• Storage buffer: PBS (pH 7.2), less than 0.1% sodium azide and 2 mg/ml BSA</li> <li>• Detects endogenous levels of total S6 ribosomal protein independent of phosphorylation</li> <li>• Application: Immunofluorescence, Flow cytometry</li> <li>• Conjugated with dye that has excitation max at <math>\sim 490</math>nm and emission max at <math>\sim 525</math>nm</li> </ul>               | 100uL        | 2        |

**Part 6**

| No. | Name and Description  | Package size | Quantity |
|-----|---|--------------|----------|
| 1.  | <b>BS3 (bis(sulfosuccinimidyl)suberate)</b> <ul style="list-style-type: none"> <li>An amine-to-amine crosslinker that is homobifunctional, water-soluble, non-cleavable and membrane impermeable</li> <li>Contains an amine-reactive N-hydroxysulfosuccinimide (NHS) ester at each end of an 8-carbon spacer arm</li> <li>Spacer Arm Length: 11.4 Å</li> <li>Water soluble</li> <li>CAS number: 82436-77-9</li> </ul> | 10x2mg       | 2        |

**Part 7**

| No. | Name and Description  | Package size | Quantity |
|-----|---|--------------|----------|
| 1.  | <b>Cryopreservation medium with 10% DMSO</b> <ul style="list-style-type: none"> <li>Animal component-free</li> <li>Serum-free and protein-free</li> <li>For use with myeloma cell lines, human pluripotent stem cells, blood-derived cells</li> <li>Species: Human, Mouse, Non-Human Primate, Other, Rat</li> </ul>                                     | 50mL         | 1        |
| 2.  | <b>Supplement for serum-free cell culture media</b> <ul style="list-style-type: none"> <li>Contains: Bovine serum albumin, Recombinant human insulin, Human transferrin (iron-saturated), Iscove's MDM</li> <li>Species: Human, Mouse</li> <li>Cell type: Hematopoietic Stem and Progenitor Cells, Hybridomas, Other, Pluripotent Stem Cells</li> </ul> | 100ml        | 6        |

**Part 8**

| No. | Name and Description  | Package size | Quantity |
|-----|---|--------------|----------|
| 1.  | <b>Serum-free Hematopoietic Cell Medium</b> <ul style="list-style-type: none"> <li>Support the generation of LAK cells in a serum-free environment</li> <li>With L-Glutamine, gentamicin and phenol red, xenofree</li> <li>Superior media for most hematopoietic cells types including dendritic cells, lymphocytes, monocytes, macrophages and granulocytes</li> <li>Applications: Proliferation of peripheral blood lymphocytes, Proliferation of tumor infiltrating lymphocytes, Cryopreservation of human tissue, Cultivation of human monocytes and macrophages</li> </ul> | 1L           | 3        |

**Part 9**

| No. | Name and Description   | Package size | Quantity |
|-----|--|--------------|----------|
| 1.  | <b>Recombinant Human IL-6 Protein</b> <ul style="list-style-type: none"> <li>Source: E.coli</li> <li>Purity: &gt;97%, by SDS-PAGE under reducing conditions and visualized by silver stain</li> <li>Endotoxin level: &lt;0.10 EU per 1 µg</li> <li>N-terminal sequence Analysis: Pro29</li> <li>Formulation: Lyophilized from a 0.2 µm filtered solution in PBS and NaCl with BSA as a carrier protein</li> <li>Reconstitute at 100-200 µg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin</li> </ul> | 10 ug        | 4        |

- Offers submitted for products in packaging sizes other than those indicated above will be rejected.
- It is possible to make an offer for a part of an order (9 parts).
- Rules of order execution:
  - Place of delivery - the seat of the Ordering Party.

- Delivery date – up to 21 calendar days from the date of delivery of the order; If range of time given, the upper value will be considered; Offers indicating a longer period will be rejected.

### III. PLACE, DATE AND PROCEDURE OF SUBMISSION OF QUOTES

- III.1. The offer must be submitted by: **5<sup>th</sup> April 2024 at 23.59 CET.**
- III.2. The offer must be sent via e-mail to the following address: [tenders@ryvu.com](mailto:tenders@ryvu.com). The message with the offer should refer to the RFQ number indicated on the first page: **ABM – 29 03 2024 B.**
- III.3. The offer and its attachments should be prepared in Polish or English.
- III.4. The quote should include the validity period (minimum 28 calendar days from the date of submission). The Ordering Party may require Bidders to agree to an extension of the quote validity period for the period of up to next 30 calendar days.

### IV. CRITERIA FOR EVALUATION OF QUOTES

- IV.1. Offers that comply with the order description (set out in section II.) will be accepted for the evaluation of offers. Offers that do not meet the requirements will be rejected.
- IV.2. Criterion: Net price ("C") – weight: 100% (10 points)
- IV.3. Net price ("C") is considered as the total price for the execution of the order (purchase and delivery).
- IV.4. Due to the possibility of submitting offers in parts, the Ordering Party allows more than one offer to be selected.
- IV.5. As regards prices quoted in foreign currencies, in order to compare the offers they shall be converted into PLN at the average exchange rate of the National Bank of Poland (NBP) prevailing on the day of closing the tender procedure indicated in section IV.1.
- IV.6. In the Net Price criterion, points will be awarded (to two decimal places) according to the formula:  
$$\text{Criterion Net price "C"} = \frac{\text{the lowest net price offered among the bids submitted}}{\text{net price of the examined offer}} \times 10 \text{ points}$$
- IV.7. The Ordering Party will select as the most advantageous the offer that obtains the highest number of point.
- IV.8. Having to choose between quotation scored in the same number of points, the Ordering Party will call Bidders to re-present the prices.

### V. ADDITIONAL INFORMATION

- V.1. The Bidders may ask the Ordering Party to clarify the content of this Quote Request. If the request for clarification of the content of the RFQ was received later than by the end of 03<sup>rd</sup> April 2024, the Ordering Party may provide explanations or leave the application unexamined. Questions must be sent to the following e-mail address: [tenders@ryvu.com](mailto:tenders@ryvu.com).
- V.2. The Ordering Party reserves the right to change the content of the RFQ, including changes in the terms of the procedure. Bidders will be informed.
- V.3. The Ordering Party reserves the right to ask the Bidders at any stage of the evaluation of offers for additional information, documents, additions or explanations. The Ordering Party's contact with the Bidder will take place by e-mail indicated in the content of the offer sent by the Bidder.
- V.4. The Ordering Party reserves the right to close the procedure without selecting any of the offers or to cancel the procedure at any stage.
- V.5. This RFQ does not oblige the Ordering Party to conclude a contract.
- V.6. For more information, please contact Aleksandra Broda at the following email address: [tenders@ryvu.com](mailto:tenders@ryvu.com).